Literature DB >> 23316065

Toll-like receptor 4 is not targeted to the lysosome in cystic fibrosis airway epithelial cells.

Catriona Kelly1, Paul Canning, Paul J Buchanan, Mark T Williams, Vanessa Brown, Dieter C Gruenert, J Stuart Elborn, Madeleine Ennis, Bettina C Schock.   

Abstract

The innate immune response to bacterial infection is mediated through Toll-like receptors (TLRs), which trigger tightly regulated signaling cascades through transcription factors including NF-κB. LPS activation of TLR4 triggers internalization of the receptor-ligand complex which is directed toward lysosomal degradation or endocytic recycling. Cystic fibrosis (CF) patients display a robust and uncontrolled inflammatory response to bacterial infection, suggesting a defect in regulation. This study examined the intracellular trafficking of TLR4 in CF and non-CF airway epithelial cells following stimulation with LPS. We employed cells lines [16hBE14o-, CFBE41o- (CF), and CFTR-complemented CFBE41o-] and confirmed selected experiments in primary nasal epithelial cells from non-CF controls and CF patients (F508del homozygous). In control cells, TLR4 expression (surface and cytoplasmic) was reduced after LPS stimulation but remained unchanged in CF cells and was accompanied by a heightened inflammatory response 24 h after stimulation. All cells expressed markers of the early (EEA1) and late (Rab7b) endosomes at basal levels. However, only CF cells displayed persistent expression of Rab7b following LPS stimulation. Rab7 variants may directly internalize bacteria to the Golgi for recycling or to the lysosome for degradation. TLR4 colocalized with the lysosomal marker LAMP1 in 16 hBE14o- cells, suggesting that TLR4 is targeted for lysosomal degradation in these cells. However, this colocalization was not observed in CFBE41o- cells, where persistent expression of Rab7 and release of proinflammatory cytokines was detected. Consistent with the apparent inability of CF cells to target TLR4 toward the lysosome for degradation, we observed persistent surface and cytoplasmic expression of this pathogen recognition receptor. This defect may account for the prolonged cycle of chronic inflammation associated with CF.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23316065      PMCID: PMC4073939          DOI: 10.1152/ajplung.00372.2011

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  44 in total

1.  Membrane sorting of toll-like receptor (TLR)-2/6 and TLR2/1 heterodimers at the cell surface determines heterotypic associations with CD36 and intracellular targeting.

Authors:  Martha Triantafilou; Frederick G J Gamper; Rowenna M Haston; Marios Angelos Mouratis; Siegfried Morath; Thomas Hartung; Kathy Triantafilou
Journal:  J Biol Chem       Date:  2006-07-31       Impact factor: 5.157

2.  Endocytic pathways regulate Toll-like receptor 4 signaling and link innate and adaptive immunity.

Authors:  Harald Husebye; Øyvind Halaas; Harald Stenmark; Gro Tunheim; Øystein Sandanger; Bjarne Bogen; Andreas Brech; Eicke Latz; Terje Espevik
Journal:  EMBO J       Date:  2006-02-09       Impact factor: 11.598

Review 3.  Chaperones and transport proteins regulate TLR4 trafficking and activation.

Authors:  Shin-Ichiroh Saitoh
Journal:  Immunobiology       Date:  2009-02-27       Impact factor: 3.144

4.  Rab7b and receptors trafficking.

Authors:  Cecilia Bucci; Oddmund Bakke; Cinzia Progida
Journal:  Commun Integr Biol       Date:  2010-09

Review 5.  New and investigational treatments in cystic fibrosis.

Authors:  Mangala Narasimhan; Rubin Cohen
Journal:  Ther Adv Respir Dis       Date:  2011-03-03       Impact factor: 4.031

6.  Expression of the nuclear factor-κB inhibitor A20 is altered in the cystic fibrosis epithelium.

Authors:  Catriona Kelly; Mark T Williams; Kathryn Mitchell; J Stuart Elborn; Madeleine Ennis; Bettina C Schock
Journal:  Eur Respir J       Date:  2012-09-27       Impact factor: 16.671

7.  Targeted immunomodulation of the NF-kappaB pathway in airway epithelium impacts host defense against Pseudomonas aeruginosa.

Authors:  Ruxana T Sadikot; Heng Zeng; Myungsoo Joo; M Brett Everhart; Taylor P Sherrill; Bo Li; Dong-sheng Cheng; Fiona E Yull; John W Christman; Timothy S Blackwell
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

8.  Lipoteichoic acid and toll-like receptor 2 internalization and targeting to the Golgi are lipid raft-dependent.

Authors:  Martha Triantafilou; Maria Manukyan; Alan Mackie; Siegfried Morath; Thomas Hartung; Holger Heine; Kathy Triantafilou
Journal:  J Biol Chem       Date:  2004-07-09       Impact factor: 5.157

9.  Lysosome-associated small Rab GTPase Rab7b negatively regulates TLR4 signaling in macrophages by promoting lysosomal degradation of TLR4.

Authors:  Yuzhen Wang; Taoyong Chen; Chaofeng Han; Donghua He; Haibo Liu; Huazhang An; Zhen Cai; Xuetao Cao
Journal:  Blood       Date:  2007-03-29       Impact factor: 22.113

10.  TLR-4-mediated innate immunity is reduced in cystic fibrosis airway cells.

Authors:  Gerrit John; Ali O Yildirim; Bruce K Rubin; Dieter C Gruenert; Markus O Henke
Journal:  Am J Respir Cell Mol Biol       Date:  2009-06-05       Impact factor: 6.914

View more
  14 in total

1.  Induction of the inflammatory regulator A20 by gibberellic acid in airway epithelial cells.

Authors:  J A Reihill; B Malcomson; A Bertelsen; S Cheung; A Czerwiec; R Barsden; J S Elborn; H Dürkop; B Hirsch; M Ennis; C Kelly; B C Schock
Journal:  Br J Pharmacol       Date:  2015-07-21       Impact factor: 8.739

Review 2.  Cystic Fibrosis Lung Immunity: The Role of the Macrophage.

Authors:  Emanuela M Bruscia; Tracey L Bonfield
Journal:  J Innate Immun       Date:  2016-06-24       Impact factor: 7.349

3.  Connectivity mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory action in cystic fibrosis.

Authors:  Beth Malcomson; Hollie Wilson; Eleonora Veglia; Gayathri Thillaiyampalam; Ruth Barsden; Shauna Donegan; Amal El Banna; Joseph S Elborn; Madeleine Ennis; Catriona Kelly; Shu-Dong Zhang; Bettina C Schock
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-10       Impact factor: 11.205

4.  Lipopolysaccharides may aggravate apoptosis through accumulation of autophagosomes in alveolar macrophages of human silicosis.

Authors:  Shi Chen; Juxiang Yuan; Sanqiao Yao; Yulan Jin; Gang Chen; Wei Tian; Jinkun Xi; Zhelong Xu; Dong Weng; Jie Chen
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

Review 5.  Recent advances in understanding and managing cystic fibrosis transmembrane conductance regulator dysfunction.

Authors:  Uta Griesenbach; Eric W F W Alton
Journal:  F1000Prime Rep       Date:  2015-05-27

6.  Pharmacological modulation of the AKT/microRNA-199a-5p/CAV1 pathway ameliorates cystic fibrosis lung hyper-inflammation.

Authors:  Ping-Xia Zhang; Jijun Cheng; Siying Zou; Anthony D D'Souza; Jonathan L Koff; Jun Lu; Patty J Lee; Diane S Krause; Marie E Egan; Emanuela M Bruscia
Journal:  Nat Commun       Date:  2015-02-10       Impact factor: 14.919

Review 7.  Lung cell-specific modulation of LPS-induced TLR4 receptor and adaptor localization.

Authors:  Vicky Sender; Cordula Stamme
Journal:  Commun Integr Biol       Date:  2014-05-16

Review 8.  Cystic Fibrosis from Laboratory to Bedside: The Role of A20 in NF-κB-Mediated Inflammation.

Authors:  Aidan Bannon; Shu-Dong Zhang; Bettina C Schock; Madeleine Ennis
Journal:  Med Princ Pract       Date:  2015-04-25       Impact factor: 1.927

9.  Rhinovirus Load Is High despite Preserved Interferon-β Response in Cystic Fibrosis Bronchial Epithelial Cells.

Authors:  Nurlan Dauletbaev; Mithun Das; Maria Cammisano; He Chen; Sareen Singh; Cora Kooi; Richard Leigh; Trevor Beaudoin; Simon Rousseau; Larry C Lands
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

10.  Ezrin links CFTR to TLR4 signaling to orchestrate anti-bacterial immune response in macrophages.

Authors:  Caterina Di Pietro; Ping-Xia Zhang; Timothy K O'Rourke; Thomas S Murray; Lin Wang; Clemente J Britto; Jonathan L Koff; Diane S Krause; Marie E Egan; Emanuela M Bruscia
Journal:  Sci Rep       Date:  2017-09-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.